No CEO Reveal For Sanofi At J.P. Morgan, But Some Drug Updates
This article was originally published in The Pink Sheet Daily
Sanofi dodged questions about CEO succession plans at the J.P. Morgan Healthcare conference, but did confirm it filed its PCSK9 inhibitor alirocumab in the fourth quarter.
You may also be interested in...
The French pharma's abrupt dismissal of its CEO, citing execution problems with its best-selling drug and issues with management style, has investors wondering whether Chris Viehbacher should have gotten the benefit of the doubt from the company’s board, given his impressive track record.
Companies’ decision to purchase and redeem BioMarin’s priority review voucher for their PCSK9 inhibitor alirocumab sets the first public benchmark for a voucher’s value and shows the potential advantages to be gained for sponsors in a race to market.
Sandoz US president Carol Lynch talked to Scrip about its changing US portfolio, which will emphasize biosimilars, as the Novartis unit is poised to divest most of its US generics portfolio to Aurobindo.